Nevertheless, since a few PRMT5 inhibitors are currently being tested in clinical trials (e.g., GSK3326595 and JNJ-64619178) 62, 63, our findings raised a concern about PRMT5 being a therapeutic target of cancer, at least in gastric tissue. Here, PRMT5 is linked to cancer.